Tag: merger
-
Sanofi Buys Nano-Antibody Biotech in $4.8B Deal
Global drug maker Sanofi is acquiring a Belgian biotechnology company developing synthetic nanoscale therapeutic antibodies in a deal valued at $4.8 billion.
-
Blood Disorder Drug Maker Acquired in $11.6B Deal
The global pharmaceutical company Sanofi is buying Bioverativ Inc., a developer of biologics to treat hemophilia and other rare blood disorders.
-
Celgene Acquires Cancer Drug Start-Up in $7B Deal
The biopharmaceutical company Celgene Corp. is acquiring Impact Biomedicines Inc., a developer of drugs to treat a type of blood-related cancer, in a deal valued as much as $7 billion.
-
Novartis Acquires Nuclear Meds Developer in $3.9B Deal
Drug maker Novartis is purchasing a company that develops therapies and diagnostics using radio isotopes for neuroendocrine and other cancers.
-
Infographic – Google’s Largest Acquisitions
Our friends at Statista yesterday published this chart showing Google/Alphabet’s largest acquisitions over the years.
-
Engineered T-Cell Company Acquired for $11.9 Billion
A company developing personal cancer therapies that genetically engineer a patient’s immune system cells is being acquired in a deal valued at $11.9 billion.
-
Genomics Company Acquires Open-Source Biomedical Platform
A company providing whole genome analysis is acquiring an enterprise developing open-source computational software for biomedical uses, such as precision medicine.
-
Lilly Acquires Migraine Therapy Company in $960M Deal
Drug maker Eli Lilly and Company is acquiring CoLucid Pharmaceuticals, a developer of treatments for migraine pain and associated symptoms.
-
Trial to Test Stem Cells for Treating Heart Failure
A clinical trial testing a treatment for heart failure using a patient’s own bone marrow stem cells is recruiting participants at the first two study sites.
-
Novartis Acquires Sickle-Cell Drug Developer
Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million.